Leerink Partnrs Research Analysts Lower Earnings Estimates for Caribou Biosciences, Inc. (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Leerink Partnrs dropped their Q2 2024 earnings estimates for shares of Caribou Biosciences in a report released on Tuesday, May 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.47) for the quarter, down from their prior estimate of ($0.46). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q3 2024 earnings at ($0.47) EPS, Q4 2024 earnings at ($0.48) EPS, FY2024 earnings at ($1.88) EPS, FY2025 earnings at ($1.78) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at ($0.38) EPS.

Separately, HC Wainwright upped their price objective on shares of Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th.

Caribou Biosciences Price Performance

Shares of CRBU opened at $3.65 on Friday. The business’s 50-day moving average is $4.87 and its 200-day moving average is $5.38. The company has a market capitalization of $329.67 million, a price-to-earnings ratio of -2.52 and a beta of 2.56. Caribou Biosciences has a fifty-two week low of $3.44 and a fifty-two week high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.17). The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%.

Hedge Funds Weigh In On Caribou Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in shares of Caribou Biosciences by 352.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,226 shares of the company’s stock worth $59,000 after buying an additional 7,968 shares during the period. Mutual Advisors LLC acquired a new stake in shares of Caribou Biosciences in the 3rd quarter valued at $83,000. State Board of Administration of Florida Retirement System boosted its position in Caribou Biosciences by 32.0% in the third quarter. State Board of Administration of Florida Retirement System now owns 21,320 shares of the company’s stock valued at $102,000 after buying an additional 5,170 shares in the last quarter. Entropy Technologies LP bought a new position in Caribou Biosciences in the 1st quarter worth approximately $113,000. Finally, Principal Financial Group Inc. lifted its holdings in Caribou Biosciences by 32.8% during the 3rd quarter. Principal Financial Group Inc. now owns 25,198 shares of the company’s stock worth $120,000 after buying an additional 6,227 shares in the last quarter. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.